The Journal of Immunology, Vol 155, Issue 9 4504-4511, Copyright © 1995 by American Association of Immunologists

ARTICLES

Vaccination with a recombinant V alpha domain of a TCR prevents the development of collagen-induced arthritis

EF Rosloniec, DD Brand, KB Whittington, JM Stuart, M Ciubotaru and ES Ward
Veterans Affairs Medical Center, Memphis, TN 38104, USA.

A recombinant TCR domain, derived from a T cell hybridoma that recognizes an immunodominant type II collagen epitope, was used to vaccinate against collagen-induced arthritis in DBA/1 (H-2q) mice. The recombinant TCR domain comprises VA11.1-JA17 gene segments and is representative of the V alpha domains expressed by oligoclonal T cells in this disease model. Vaccination of mice 28 days before type II collagen (CII) immunization with this V alpha 11.1 domain resulted in a significantly decreased incidence of arthritis in DBA/1 mice, in contrast to vaccination with a V alpha 4-J alpha 40 domain derived from an encephalitogenic T cell hybridoma specific for MBP. Disease blockade is accompanied by a reduction in T and B cell responses to both the immunogen bovine CII and the autoantigen murine CII. V alpha 4 and V alpha 11.1 domains were found to be highly immunogenic in DBA/1 mice, inducing both T cell proliferation and the production of V alpha specific Abs, indicating that the vaccination effect of V alpha 11.1 is specific. This is the first report of V alpha-directed immunotherapy in an autoimmune disease model and demonstrates the potential use of recombinant TCR vaccines in the treatment of autoimmune diseases that involve oligoclonal autoreactive T cells.

This article has been cited by other articles:

				J. C. Huang, M. Vestberg, A. Minguela, R. Holmdahl, and E. S. Ward Analysis of autoreactive T cells associated with murine collagen-induced arthritis using peptide-MHC multimers Int. Immunol., February 1, 2004; 16(2): 283 - 293. [Abstract] [Full Text] [PDF]

				R. H. McMahan, L. Watson, R. Meza-Romero, G. G. Burrows, D. N. Bourdette, and A. C. Buenafe Production, Characterization, and Immunogenicity of a Soluble Rat Single Chain T Cell Receptor Specific for an Encephalitogenic Peptide J. Biol. Chem., August 15, 2003; 278(33): 30961 - 30970. [Abstract] [Full Text] [PDF]

				S. M. Thirdborough, J. N. Radcliffe, P. S. Friedmann, and F. K. Stevenson Vaccination with DNA Encoding a Single-Chain TCR Fusion Protein Induces Anticlonotypic Immunity and Protects against T-Cell Lymphoma Cancer Res., March 1, 2002; 62(6): 1757 - 1760. [Abstract] [Full Text] [PDF]

				D. D. Brand, L. K. Myers, K. B. Whittington, K. A. Latham, J. M. Stuart, A. H. Kang, and E. F. Rosloniec Detection of Early Changes in Autoimmune T Cell Phenotype and Function Following Intravenous Administration of Type II Collagen in a TCR-Transgenic Model J. Immunol., January 1, 2002; 168(1): 490 - 498. [Abstract] [Full Text] [PDF]

				E. A. E. van Tienhoven, C. P. M. Broeren, A. Noordzij, J. P. A. Wagenaar, W. van Eden, and M. H. M. Wauben Nasal application of a naturally processed and presented T cell epitope derived from TCR AV11 protects against adjuvant arthritis Int. Immunol., December 1, 2000; 12(12): 1715 - 1721. [Abstract] [Full Text] [PDF]

				A. Qadri, J. Thatte, C. G. Radu, B. Ober, and E. S. Ward Characterization of the interaction of a TCR {alpha} chain variable domain with MHC II I-A molecules Int. Immunol., June 1, 1999; 11(6): 967 - 977. [Abstract] [Full Text] [PDF]

				C. P. Wong, C. Y. Okada, and R. Levy TCR Vaccines Against T Cell Lymphoma: QS-21 and IL-12 Adjuvants Induce a Protective CD8+ T Cell Response J. Immunol., February 15, 1999; 162(4): 2251 - 2258. [Abstract] [Full Text] [PDF]

				V. Kumar, F. Aziz, E. Sercarz, and A. Miller Regulatory T Cells Specific for the Same Framework 3 Region of the Vbeta 8.2 Chain Are Involved in the Control of Collagen II-induced Arthritis and Experimental Autoimmune Encephalomyelitis J. Exp. Med., May 19, 1997; 185(10): 1725 - 1733. [Abstract] [Full Text] [PDF]